AUGUST 2013 Summary of Changes to the Queensland Health List of Approved Medicines (LAM)
as recommended by the Queensland Health Medicines Advisory Committee (QHMAC)
ITEM
#
MEDICINE
DECISION &
DATE
EFFECTIVE
RESTRICTION
13/071
IPILIMUMAB
INJECTION 360mg
(maximum amount)
ADDED
01-Aug-13
Specialist Staff for use as per the Efficient Funding of Chemotherapy – Section 100 Arrangements
Supplement of the PBS (Refer to www.pbs.gov.au)
13/070
OMEPRAZOLE
MAGNESIUM TABLET
10mg
ADDED
01-Oct-13
Specialist Staff and Country Medical Superintendents for oral administration in children under 1 year of
age. (Tablets do not disperse evenly; not suitable for use in 6Fr NG tube - use omeprazole suspension)
13/069
PNEUMOCOCCAL
CONJUGATE
VACCINE (13VALENT) INJECTION,
Pre-filled syringe
0.5mL (Prevenar 13®)
ADDED
01-Oct-13
Adults at increased risk of invasive pneumococcal infection due to functional or anatomical asplenia.
13/083
RALTEGRAVIR Tablet
25mg, 100mg
ADDED 01Sep-13
(to
be reflected in
1 Oct LAM)
Specialist Staff for use in accord with Highly Specialised Drugs Program indications
13/048
SODIUM CHLORIDE
COMPOUND (Ringers
lactate with glucose)
Powder for
reconstitution – sachet
(4) plus bottle with
paediatric tip (FLO kids
Sinus Care Starter
Kit®)
ADDED
01-Oct-13
For initial supply post ENT surgery and sinus irrigation for children with chronic rhinosinusitis which may
co-exist with cystic fibrosis and asthma.
[Note: This item was discussed again at the September 2013 QHMAC meeting and further changes to its
restriction were recommended. Refer to the September 2013 Summary of Changes, when available, for
the revised LAM restriction].
ITEM
#
MEDICINE
DECISION &
DATE
EFFECTIVE
RESTRICTION
VITAMIN, FAT
SOLUBLE
COMPOUND IN
TOCOPHEROL PEG
SUSPENSION
chewable tablet (60),
soft gel capsule (60),
paediatric liquid 60mL
(AquADEKs)
AMISULPRIDE ORAL
LIQUID 100 mg per
mL, TABLET 100mg,
200mg, 400mg
ADDED
01-Oct-13
Paediatricians, in consultation with RCH’s Paediatric Gastroenterology and Hepatology Service or Cystic
Fibrosis Clinic, for infants and children with cholestasis (biliary atresia, alagilles, cystic fibrosis) and FSV
deficiency resistant to standard oral FSV supplements. (Children should have documented deficiency of
Vit K [abnormal Prothrombin time correctable with Vit K IMI], A, D and E on blood testing.)
Where an item is not TGA approved, patients should be made fully aware of its status and appropriate
consent obtained”.
AMENDED
01-Oct-13
For use as per the PBS indications following failure of risperidone or olanzapine
13/076
APIXABAN Tablet
2.5mg
For orthopaedic prophylaxis of venous thromboembolism in total hip and knee replacement
13/073B
ARIPIPRAZOLE
TABLET 5mg, 10mg,
15mg, 20mg, 30mg
AMENDED
01-Sep-13
(to be reflected
in 1 Oct LAM)
AMENDED
01-Oct-13
13/073C
ASENAPINE WAFER
5mg, 10mg
AMENDED
01-Oct-13
For use as per the PBS indications following failure of risperidone or olanzapine
13/073D
OLANZAPINE
TABLET 2.5mg, 5mg,
7.5mg, 10mg; WAFER
5mg, 10mg, 20mg
AMENDED
01-Oct-13
For use as per the PBS indications
13/051
13/073A
For use as per the PBS indications following failure of risperidone or olanzapine
Page 2 of 6
ITEM
#
MEDICINE
DECISION &
DATE
EFFECTIVE
RESTRICTION
13/070A
OMEPRAZOLE
MAGNESIUM TABLET
20mg
AMENDED
01-Oct-13
Specialist Staff and Country Medical Superintendents for oral administration in children under 1 year of
age. (Tablets do not disperse evenly; not suitable for use in 6Fr NG tube - use omeprazole suspension)
13/073E
QUETIAPINE
IMMEDIATE
RELEASE TABLET
25mg, 100mg;
MODIFIED RELEASE
TABLET 50mg,
200mg, 300mg, 400mg
RISPERIDONE
TABLET and ORALLY
DISINTEGRATING
TABLET
0.5mg, 1mg, 2mg,
3mg, 4mg;
ORAL LIQUID
1mg per mL, 100mL
VITAMIN COMPOUND
WITH MINERALS,
CHEWABLE TABLET
(Centrum Kids®
Chewable Tablets)
AMENDED
01-Oct-13
For use as per the PBS indications following failure of risperidone or olanzapine
AMENDED
01-Oct-13
For use as per the PBS indications
AMENDED
01-Oct-13
Patients unable to swallow tablets
13/073G
ZIPRASIDONE
CAPSULE 20mg,
40mg, 60mg, 80mg
AMENDED
01-Oct-13
For use as per the PBS indications following failure of risperidone or olanzapine
13/028
CINACALCET TABLET
30mg, 60mg, 90mg
13/073F
13/063E
DEFERRED
Page 3 of 6
ITEM
#
13/066
13/074
13/063A
13/063C
13/063B
13/063D
MEDICINE
DECISION &
DATE
EFFECTIVE
LACTOBACILLUS
ACIDOPHILUS &
bifidobacterium bifidum
CAPSULE 250mg
SEVOFLURANE
INHALATION
ANAESTHETIC 250mL
ALPROSTADIL
INJECTION 5microgram
in 1mL
DEFERRED
BISACODYL MAGNESIUM CITRATE
(Pack containing 3 x
5mg bisacodyl tablets
plus 1 x 10mg bisacodyl
suppository and 1 x
sachet magnesium
citrate effervescent
[equiv to 3g magnesium
oxide (Go Kit Plus®)
BISACODYL
PAEDIATRIC
SUPPOSITORIES 5mg
(6)
SODIUM
HYALURONATE
Intraocular Solution for
Injection 10mg per mL,
1mL
DELETED
01-Oct-13
RESTRICTION
DEFERRED
DELETED
01-Oct-13
DELETED
01-Oct-13
DELETED
01-Oct-13
Page 4 of 6
ITEM
#
MEDICINE
DECISION &
DATE
EFFECTIVE
13/075
PALIVIZUMAB
POWDER FOR
INJECTION 50mg,
100mg
NOT ADDED
13/067
RISEDRONATE
SODIUM TABLET
ENTERIC COATED
35mg
NOT ADDED
13/049
SODIUM CHLORIDE
COMPOUND (Sodium
chloride, sodium
bicarbonate, potassium
chloride, calcium,
magnesium chloride
hexahydrate) Nasal
Spray 15mL (FLO Baby
Saline + Nasal Spray)
GABAPENTIN TABLET
300mg
NOT ADDED
COUNCIL OF
AUSTRALIAN
THERAPEUTIC
ADVISORY GROUPS
(CATAG) UPDATE
CYCLOPHOSPHAMIDE
Tablet 50mg
FOR INFORMATION HYDROXYETHYL
STARCH Solutions for
infusion
NOTED
13/068
7.
13/072
13/065
RESTRICTION
NOT
AMENDED
NOTED
NOTED
Page 5 of 6
ITEM
#
MEDICINE
DECISION &
DATE
EFFECTIVE
13/019
MAGNESIUM SULFATE
in water for Injection,
prefilled syringe (PFS)
4g in 20mL (20%), and
10g in 50mL (20%)
NOTED
12/T09
SOA –
LOW MOLECULAR
WEIGHT HEPARINS
(LMWHs)
NOTED
RESTRICTION
Page 6 of 6